Condition
Squamous Cell Carcinoma of Skin
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (2)
P 2 (1)
Trial Status
Withdrawn1
Terminated1
Not Yet Recruiting1
Completed1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04913220Phase 1Terminated
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
NCT07339176Phase 1Not Yet Recruiting
Intratumoral N17350 in Advanced Solid Tumors
NCT06606028Recruiting
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
NCT02218164Phase 2CompletedPrimary
Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
NCT02321982Not ApplicableWithdrawn
Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery
Showing all 5 trials